CNS Pharmaceuticals
CNSP | NASDAQ
$3.48
+$0.59 (+20.42%)
At close: Nov 16, 2026, 4:00 PM ET
$3.60
+$0.12 (+3.45%)
After-hours:
Nov 16, 2026, 5:54 PM ET
CNS Pharmaceuticals Company Profile
Company profile explainedCompany Profile
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements. These include licensing arrangements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Additionally, CNS Pharmaceuticals has a development agreement in place with WPD Pharmaceuticals Inc. and a collaborative partnership with Reata Pharmaceuticals, Inc. The company was founded in 2017 and is headquartered in Houston, Texas.
Key Executives
| Name | Position |
|---|---|
| Rami Levin | Chief Executive Officer, President & Director |
| Eric Faulkner | Chief Technology Officer |
| Steve O'Loughlin | Chief Financial Officer |
| Dylan Wenke | Chief Business Officer |
| E. Lynne Kelley | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 02, 2026 | 8-K | Current Report |
| Aug 25, 2026 | DEFA14A | Filing |
| Aug 21, 2026 | DEF 14A | Filing |
| Aug 18, 2026 | 4 | Filing |
| Aug 18, 2026 | 3 | Filing |
| Aug 18, 2026 | 4 | Filing |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 12, 2026 | 10-Q | Quarterly Report |
| Jul 02, 2026 | 8-K | Current Report |
| May 26, 2026 | EFFECT | Filing |
CNS Pharmaceuticals
| Country | United States |
| IPO Date | Nov 8, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Rami Levin |
Contact Details
2100 West Loop South Houston,
Texas 77027 United States
Stock Details
| Ticker Symbol | CNSP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001729427 |
| CUSIP Number | 18978H508 |
| ISIN Number | US18978H5081 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove CNSP